WO1992004358A1 - Method and reagent for sulfurization of organophosphorous compounds - Google Patents
Method and reagent for sulfurization of organophosphorous compounds Download PDFInfo
- Publication number
- WO1992004358A1 WO1992004358A1 PCT/US1990/004994 US9004994W WO9204358A1 WO 1992004358 A1 WO1992004358 A1 WO 1992004358A1 US 9004994 W US9004994 W US 9004994W WO 9204358 A1 WO9204358 A1 WO 9204358A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- organic
- amine
- sulfur
- tertiary amine
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 238000005987 sulfurization reaction Methods 0.000 title claims description 39
- 150000002903 organophosphorus compounds Chemical class 0.000 title claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 35
- 229940058344 antitrematodals organophosphorous compound Drugs 0.000 title description 2
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000002773 nucleotide Substances 0.000 claims abstract description 47
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 41
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims abstract description 36
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 23
- 239000011593 sulfur Substances 0.000 claims abstract description 22
- 239000002904 solvent Substances 0.000 claims abstract description 19
- 150000003512 tertiary amines Chemical class 0.000 claims abstract description 13
- 150000002148 esters Chemical class 0.000 claims abstract description 12
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims abstract description 9
- FUWGSUOSJRCEIV-UHFFFAOYSA-N phosphonothioic O,O-acid Chemical class OP(O)=S FUWGSUOSJRCEIV-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000005270 trialkylamine group Chemical group 0.000 claims abstract 15
- 150000008301 phosphite esters Chemical class 0.000 claims abstract 3
- -1 aromatic tertiary amine Chemical class 0.000 claims description 26
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 24
- 239000002777 nucleoside Substances 0.000 claims description 18
- 239000003960 organic solvent Substances 0.000 claims description 14
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 claims description 14
- 125000003835 nucleoside group Chemical group 0.000 claims description 11
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 150000005690 diesters Chemical class 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 claims 1
- XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical compound OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 claims 1
- 125000001302 tertiary amino group Chemical group 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 abstract description 20
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 abstract description 8
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 abstract 3
- 229940043279 diisopropylamine Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 description 19
- 108091034117 Oligonucleotide Proteins 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 7
- 102000053602 DNA Human genes 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000000074 antisense oligonucleotide Substances 0.000 description 6
- 238000012230 antisense oligonucleotides Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 150000008300 phosphoramidites Chemical class 0.000 description 3
- 125000005642 phosphothioate group Chemical group 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000005289 controlled pore glass Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JTGUPKKZPSNUIX-UHFFFAOYSA-N methylperoxyphosphonamidous acid Chemical class COOP(N)O JTGUPKKZPSNUIX-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JEINKDNZGFNZGC-UHFFFAOYSA-N (2-cyanoethoxyamino)phosphonous acid Chemical class OP(O)NOCCC#N JEINKDNZGFNZGC-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UBTJZUKVKGZHAD-UHFFFAOYSA-N 1-[5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OC)=CC=1)(C=1C=CC=CC=1)OCC1C(O)CC(N2C(NC(=O)C(C)=C2)=O)O1 UBTJZUKVKGZHAD-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical compound CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 108020002494 acetyltransferase Proteins 0.000 description 1
- 102000005421 acetyltransferase Human genes 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- PREFYZZMLJYIQN-UHFFFAOYSA-N aminophosphanyloxymethane Chemical compound COPN PREFYZZMLJYIQN-UHFFFAOYSA-N 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- CCVKPWUMYBYHCD-UHFFFAOYSA-N oxolane;pyridine Chemical compound C1CCOC1.C1=CC=NC=C1 CCVKPWUMYBYHCD-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical group [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Definitions
- This invention relates to the sulfurization of phosphites and phosphonous esters. In another aspect it relates to phosphorothioate analogs of nucleic acids. In another aspect it relates to methods for synthesizing such analogs. In a further aspect it relates to reagents useful in the sulfurization of phosphites and phosphonous esters, for example, the synthesis of phosphorothioate analogs of nucleic acids.
- Nucleic Acids occur in nature as chains of either ribonucleotides or deoxyribonucleotides, the individual nucleotides being linked to each other by phosphodiester bonds between the ribose and deoxyribose sugars which form, respectively, the backbones of ribo- nucleic acids (RNA) or deoxyribonucleic acids (DNA) .
- RNA ribo- nucleic acids
- DNA deoxyribonucleic acids
- DNA and RNA oligonucleotides are expected to play an increasingly important role in medical diagnostic and therapeutic applications.
- oligonucleotides have been shown to be useful in a variety of "probe" assays for viral and bacterial diseases and for the detection of genetic abnormalities.
- the "probe” is typically an oligonucleo- tide selected to be complementary to a RNA or DNA sequence which is unique to the organism or genetic defect to be detected (Matthews et al., Anal. Bioche .. Vol. 169, (1988)) . It has also been observed that oligonucleotides which are complementary to messenger RNA (antisense oligonucleotides) can be introduced to a cell and arrest the translation of the mRNA. This arrest is believed to result from the hybridization of the antisense oligonu- cleotide to the mRNA. See, for example, Stephenson, et al., Proc. Natl. Acad. Sci..
- a virus infecting a cell reproduces its genetic information by using the biological machinery of the infected cell. Transcription and trans- lation of that information by the cellular ribosomes are essential to viral reproduction. Thus, if expression of the viral gene can be interrupted, the virus cannot replicate or may replicate at such a slow rate as to give the host's immune system a better opportunity to combat the infection.
- oligonucleotides in viral therapy by designing an oligonucleotide with a nucleotide sequence complementary to a sequence of virally expressed mRNA which must be translated if viral replica- tion is to be successful.
- Introduction of the antisense oligonucleotide to the cell permits it to hybridize with and prevent, or at least inhibit, this essential transla ⁇ tion.
- Phosphorothioate analogs of oligonucleotide probes are also useful as replacements for conventional probes for diagnostic and therapeutic applications.
- only a few techniques have been reported for the synthesis of phosphorothioate analogs of nucleic acids, all of them cumbersome and not well adapted for use with currently available automated nucleic acid synthesizers.
- One reported synthetic technique uses presynthesized nucleotide di ers. The synthesis of the full array of sixteen dimers necessary for the proce ⁇ dure is both laborious and expensive. (Connoly et al., Bioche ⁇ t.. 23, 3443 (1984).
- a more preferred procedure would permit use of the highly reactive, commercially available nucleoside- phosphoramidite monomers currently employed with nucleic acid synthesizers. Such monomers are actually used in processes for preparing phosphorothioate analogs. How ⁇ ever, the sulfurization of phosphorous in the phosphite intermediate has been very troublesome. For example, elemental sulfur in pyridine at room temperature requires up to 16 hours to produce the internucleotide phosphorothioate triester 12 as shown in Fig. I. (P.S. Nelson, et al., J. Or ⁇ . Chem.. 49, 2316 (1984); P.M.S. Burgers, et al., Tet. Lett.. 40, 3835 (1978)).
- Nucleotide A subunit of a nucleotide acid consisting of a phosphate group, a 5 carbon sugar ring and nitrogen containing purine or pyrimidine ring.
- RNA the nucleotide acid
- 5 carbon sugar is ribose.
- DNA it is 2-deoxyribose.
- Nucleotide multimer A chain of two or more nucleotides linked by phosphorodiester or phosphonodiester bonds, or analogs thereof.
- Oligonucleotide A nucleotide multimer generally about 10 to 125 nucleotides in length, but which may be greater than 125 nucleotides in length. They are usually obtained by synthesis from nucleotide monomers, but may also be obtained by enzymatic means.
- Nucleotide multimer probe A nucleotide multimer having a nucleotide sequence complementary with a target nucleotide sequence contained within a second nucleotide multimer, usually a polynucleotide.
- the probe is selected to be perfectly complementary to the corresponding base in the target sequence. However, in some cases it may be adequate or even desirable that one or more nucleotides in the probe not be complementary to the corresponding base in the target sequence, or that various moieties of synthetic origin either replace a nucleotide within the probe or be inserted between bases of the probe.
- the probe is labeled when used for diagnostic purposes.
- Oligonucleotide probe A probe of synthetic or enzymatic origin usually having less than about 125 nucleotides, but which may contain in excess of 200 nucleotides.
- Hybridization The formation of a "hybrid", which is the complex formed between two nucleotide multi- mers by Watson-Crick base pairings between the complemen ⁇ tary bases.
- the present invention provides a reagent which is suitable for the convenient and efficient sul ⁇ furization of organic phosphites (i.e. trivalent phosphor ⁇ us bonded to three oxy groups with at least one thereof being an organic-oxy group) and organic phosphonous esters (i.e. trivalent phosphorous bonded to only two oxy groups) , to form the corresponding thiophosphorus acid derivatives (specifically, phosphorothioates or phosphononothioates, respectively) .
- organic phosphites i.e. trivalent phosphor ⁇ us bonded to three oxy groups with at least one thereof being an organic-oxy group
- organic phosphonous esters i.e. trivalent phosphorous bonded to only two oxy groups
- the invention is particularly suited to sulfurizing a suitably protected inter-nucleotide, either 3'-5' or 2'-5* phosphite or phosphonous linkages contained in oligonucleotides and ribonucleotide multimers in solution or on a solid support for the manual or automated synthesis of phosphothioate oligonucleotides.
- the present invention provides, in one aspect, a reagent and process using that reagent suitable for adding "sulfur" to a phosphite or phosphonous intermediate such as the kind H (see Fig. 1 in which some preferred substituents are listed) to produce a phosorothioate or phosphonothioate of the kind 12. (see Fig.
- the reagent comprises a mixture of elemental sulfur, a solvent for sulfur, and a tertiary alkyl amine.
- the preferred reagent is: 0.2M elemental sulfur in a mixture comprising 50% carbon disulfide and 50% diisopropylethylamine.
- Other reagents of the present invention include:
- Fig. 3 illustrates a sulfurization process according to the invention as embodied in the synthesis of phosphorothioate analogs of oligonucleotides.
- Fig. 1 shows the sulfurization of an oligonu ⁇ cleotide phosphite or phosphonous ester to form a phosphorothioate triester, or phosphonothioate diester, of a nucleic acid, some preferred substituents listed.
- Fig. 2 illustrates the formation of an oligonu ⁇ cleotide phosphite triester or phosphonous diester useful in the invention, with some preferred substituents listed.
- Fig. 3 illustrates assembly of an oligonucleo ⁇ tide phosphorothioate, involving sulfurization of oligonu ⁇ cleotide phosphites using a reagent of the present inven ⁇ tion and its conversion to the corresponding phosphorothi- oate.
- the reagent of the present invention comprises a mixture of elemental sulfur, an organic solvent for sulfur, and a non-aromatic tertiary amine.
- a non-aromatic amine is meant an amine which is not a member of an aromatic ring. However this term does not exclude an aromatic group bonded to the nitrogen of an amine group.
- the solvent for sulfur can be selected from solvents such as carbon disulfide, toluene, benzene or ethyl alcohol. Carbon disulfide is preferred as it is a particularly effective solvent for sulfur.
- the mixture can optionally include other substances, for example aromatic amines, such as pyridine.
- the useful tertiary amines include, for example, triethylamine and diisopro- pylethylamine. Diisopropylethylamine is preferred.
- composition of the reagent can vary over a wide range and the particular formulation which yields the best results can depend upon the phosphite or phosphonous ester being sulfurized.
- the most effective formulation of the reagent for a specific reaction can be determined by varying the components of the mixture.
- particular formulations may be found practically difficult to work with. For example, it was found that in a formulation in which l,8-diazabicyclo[5,4,0]undec-7-ene was used as the tertiary amine, sulfur precipitated out from the carbon disulfide solution.
- the reagents of the present invention are useful for the sulfurization of organic phosphites or phosphonous esters to form the corresponding phosphorothioate.
- the starting organophosphorus compound, and its corresponding phosphorothioate produced by the method of the present invention have the formulae:
- R 1f R 2 , and R 3 may be the same or different and are preferrably selected from organic moieties such as optionally substituted alkyl, alkoxy, phenyl, phenoxy, and tertiary a ino, and analogues of the foregoing.
- R, and R j may be ribonucleosides and deoxyribonucleosides.
- the reagents of the present invention are particularly useful in the synthesis of phosphorothioate analogs of oligonucleotides from a phosphite or phospho ⁇ nous ester in which R 1 and R ? are nucleosides, particularly suitably protected nucleosides.
- R 3 is a group which can be selectively removed (cleaved) following sulfurization. Examples of such groups include methoxy, and ⁇ -cyanoethoxy.
- R 3 need not be a group which can be selectively removed following sulfurization.
- R 3 could be methyl.
- Phosphites and phosphonous esters of the foregoing type are readily obtained using the processes of U.S. Patent No. 4.625,677 and U.S. Patent No. 4,458,066 (the disclosures of these patents, and all other references cited herein, being incorporated into this application by reference) .
- Figure 2 illustrates the assembly of a dinucleo- side phosphite or phosphonous ester 15. from compounds of the type 13. (phosphoramidites or phosphona idites) and 14 (nucleotides) .
- phosphoramidites or phosphona idites compounds of the type 13.
- phosphona idites compounds of the type 13.
- 14 nucleotides
- Sulfurization is preferably carried out after the addition of each nucleoside although sulfurization may be deferred and carried out on the assembled oligomer.
- a preferred reagent for the sulfurization of phosphites or phosphonous esters, particularly the internucleotides obtained from the phosphoramidite process is 0.2M elemental sulfur dissolved in an equal volume mixture of carbon disulfide and diisopropylethylamine.
- Examples 1 and 2 below describe in detail the use of a sulfurizing reagent of the present invention for automated synthesis of phosphorothioates of a different nucleotide multimers.
- Examples 3 and 4 describe the use of a different sulfurizing reagent of the present invention for automated synthesis of nucleotide multimers.
- Examples 5 and 6 are similar to Examples 1 through 4 but illustrate the use of different reagents.
- Example 7 describes the use of a further sulfurizing agent of the present invention for automated synthesis of various phosphorothioate nucleotide multimers, while Example 8 is similar to Example 7 but describes the use of different reagents.
- Examples 9 through 11 also describe the use of sulfurizing reagents of the present invention in the automated synthesis of various nucleotide multimers.
- Example 12 illustrates the Tm (melting temperature) of hybrids formed by the hybridization of phosphorothioate analogs with a complementary RNA sequence.
- Example 1 illustrates the Tm (melting temperature) of
- Sulfurization was achieved by delivering a 0.2 molar solution of elemental sulfur in 50% carbon disulfide/ 50% diisopropylethylamine, (all percentages by volume unless otherwise indicated) for 15 seconds and letting it stand in the 15 ⁇ mol T-column for 30 seconds. After the sulfurization, the column and the delivery lines were washed with acetonitrile before beginning the next cycle of addition of the next base of the sequence.
- the synthetic procedure is initiated using 5'-O-dimethoxytrityl-thymidine linked to controlled pore glass (CPG) , reagent 16, as described, for example, in U.S. Patent No. 4,458,066.
- CPG controlled pore glass
- DMT 5'-dimethoxy- trityl
- Any unreacted 12 is capped by treatment with acetic anhydride and dimethylaminopyridine.
- the dimer 12 is sulfurized with the same sulfurization reagent consisting of 0.2M sulfur in 50% CS 2 /50% DIEA to form the phosphorothioate triester 22. ' The 5'-protecting group is then removed as before to form dimer 21 and the trimer (not shown) assembled using the thymidine phosphoramidite 18 which is then sulfurized and deprotected, followed by assembly of a tetramer using thymidine phosphoramidite 18. Sulfurization of the tetramer and removal of the 5'- protecting group in the same manner as described, provides tetramer 22.
- Example 1 The procedure of Example 1 was repeated except using as a sulfurization reagent, 0.2M sulfur in 50% CS 2 /50% triethylamine ("TEA"), to successfully produce PS-TTTT.
- a sulfurization reagent 0.2M sulfur in 50% CS 2 /50% triethylamine ("TEA")
- Example 2 The procedure of Example 2 was repeated except using as a sulfurization reagent 0.2M sulfur in 50% CS 2 /50% TEA. In both this Example and in Example 3, the respective sulfurized nucleotide multimers were obtained.
- the sulfurization reagent of Examples 1 and 2 is preferred over that of this Example and Example 3, since it was found that when TEA was used as the tertiary amine rather than DIEA, a brown glue like substance started appearing in the flask after about 6 hours, which was not the case when DIEA was used (the S/CS 2 /DIEA showing no signs of instability even after 3 days) .
- Example 5 Example 5
- Example 7 The procedures of Examples 3 and 4 were repeated to again successfully produce the PS-TTTT and a. (the 26 er) , but using the methoxy phosphoramidites of Example 5.
- Example 7 The procedures of Examples 3 and 4 were repeated to again successfully produce the PS-TTTT and a. (the 26 er) , but using the methoxy phosphoramidites of Example 5.
- a sulfurization reagent was prepared consisting of 0.2M S in 25% CS 2 /25% pyridine/50% TEA. The procedure of Example 1 was then repeated except using the foregoing sulfurization reagent. The procedure of Example 2 was also repeated, to prepare a (the 26-mer) , using the foregoing sulfurization reagent. In addition, using the foregoing sulfurization reagent and the procedure of
- Example 2 the following nucleotide multimers were also successfully prepared.
- Example 8 the following nucleotide multimers were also successfully prepared.
- Example 9 The procedure of Example 7 was repeated, but using the methoxy phosphoramidites of the nucleotides, to successfully prepare the sulfurized oligomers a., _, c., and d.
- Example 9 The procedure of Example 7 was repeated, but using the methoxy phosphoramidites of the nucleotides, to successfully prepare the sulfurized oligomers a., _, c., and d.
- Example 1 The procedure of Example 1 was again essentially repeated except using the methyl, rather than the ⁇ - cyanoethoxy, phosphonamidite of the T-nucleoside having the formula:
- the sulfurization reagent used was 0.2M sulfur in 25% CS 2 /25% pyridine/50% TEA. Further, in order to cleave the PS-nucleotide from the resin, the resin was treated at room temperature with 1 ml of a 1:1 (by volume) mixture of ethylenediamine/EtOH for 6 hours.
- Example 10 The procedure of Example 2 was essentially repeated to prepare the sulfurized 15-mer of c, except using the methyl phosphonamidite and the cleavage procedure Example 9. The resulting oligomer has the sequence c in which the nucleosides are linked by methyl phosphonothioate diester groups.
- Example 11 The procedure of Example 2 was essentially repeated to prepare the sulfurized 15-mer of c, except using the methyl phosphonamidite and the cleavage procedure Example 9. The resulting oligomer has the sequence c in which the nucleosides are linked by methyl phosphonothioate diester groups.
- Example 9 was repeated except the sulfurizing reagent used as 0.2M sulfur in 50% CS 2 /50% DIEA (which as previously mentioned is preferred over that using TEA, or that in which pyridine is additionally present) .
- the resulting product was again the PS-TTTT oligomer in which the nucleotides are linked by methyl phosphonothioate diester groups of the formula: I
- the table below compares the Tm of two phosphor ⁇ othioate analogs with normal nucleotide multimers.
- the P 32 labeled nucleotide multimer was hybridized with E. coli RNA in 0.48 H phosphate buffer, the hybrid bound to hydroxyapatite resin and the thermal stability measured in 0.1J4 phosphate buffer.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
Abstract
A composition suitable for sulfurizing an organophosphite. The reagent comprises a solution of sulfur and a tertiary amine, in a suitable solvent such as carbon disulfide. The tertiary amine is preferably an optionally substituted trialkyl amine, for example triethylamine or diisopropylamine. A method is also provided in which phosphites or phosphonous esters are sulfurized to their corresponding phosphorothioates or phosphonothioates, respectively, using compositions of the present invention. This method has particular application to produce internucleotide phosphorothioate or phosphonothioate bonds in a nucleotide multimer.
Description
DESCRIPTION
METHOD AND REAGENT FOR SULFURIZATION OF ORGANOPHOSPHOROUS COMPOUNDS
Field of the Invention
This invention relates to the sulfurization of phosphites and phosphonous esters. In another aspect it relates to phosphorothioate analogs of nucleic acids. In another aspect it relates to methods for synthesizing such analogs. In a further aspect it relates to reagents useful in the sulfurization of phosphites and phosphonous esters, for example, the synthesis of phosphorothioate analogs of nucleic acids.
gacKqround of the Invention
Nucleic Acids occur in nature as chains of either ribonucleotides or deoxyribonucleotides, the individual nucleotides being linked to each other by phosphodiester bonds between the ribose and deoxyribose sugars which form, respectively, the backbones of ribo- nucleic acids (RNA) or deoxyribonucleic acids (DNA) . Apart from their role in naturally occurring phenomena, DNA and RNA, particularly DNA and RNA oligonucleotides, are expected to play an increasingly important role in medical diagnostic and therapeutic applications. For example, oligonucleotides have been shown to be useful in a variety of "probe" assays for viral and bacterial diseases and for the detection of genetic abnormalities. In these assays, the "probe" is typically an oligonucleo- tide selected to be complementary to a RNA or DNA sequence which is unique to the organism or genetic defect to be detected (Matthews et al., Anal. Bioche .. Vol. 169, (1988)) .
It has also been observed that oligonucleotides which are complementary to messenger RNA (antisense oligonucleotides) can be introduced to a cell and arrest the translation of the mRNA. This arrest is believed to result from the hybridization of the antisense oligonu- cleotide to the mRNA. See, for example, Stephenson, et al., Proc. Natl. Acad. Sci.. USA, 75, 285 (1978) and Za ecnick, et al., Proc. Natl. Acad. Sci.. USA, 75, 280 (1978) . The ability of antisense oligonucleotides to inhibit or prevent mRNA translation suggests their ap¬ plication in antiviral therapy. A virus infecting a cell reproduces its genetic information by using the biological machinery of the infected cell. Transcription and trans- lation of that information by the cellular ribosomes are essential to viral reproduction. Thus, if expression of the viral gene can be interrupted, the virus cannot replicate or may replicate at such a slow rate as to give the host's immune system a better opportunity to combat the infection.
It has been proposed to use oligonucleotides in viral therapy by designing an oligonucleotide with a nucleotide sequence complementary to a sequence of virally expressed mRNA which must be translated if viral replica- tion is to be successful. Introduction of the antisense oligonucleotide to the cell permits it to hybridize with and prevent, or at least inhibit, this essential transla¬ tion.
Conventional phosphodiester antisense oligonu- cleotides have been reported to exhibit significant shortcomings as antisense oligonucleotides. One limita¬ tion is that they are highly subject to degradation by nucleases, enzymes which breakdown nucleic acids to permit recycling of the nucleotides. In addition, most cells are
negatively charged. As a result, a phosphodiester oligo¬ nucleotide does not readily penetrate the cell membrane because of the density of negative charge in the backbone of the oligonucleotide. It has been proposed to modify oligonucleotides to overcome these shortcomings. One such proposal has been to use non-polar analogs of conventional phospho¬ diester oligonucleotides. Such analogs retain the ability to hybridize with a complementary sequence and would be expected to enter the cell more readily and be less resistive to nuclease degradation. Promising results have been obtained with methyl phosphonate analogs. See Agris et al., Biochemistry 25. 1228 (1986). More recently phosphorothioate analogs, i.e., nucleic acids in which one of the non-bridging oxygen atoms in each inter-nucleotide linkage has been replaced by a sulfur atom, have also been shown to possess the ability to block mRNA translation. In at least one case, inhibition of expression of the chlora phenicol acetyltransferase gene, a phosphorothioate analog has been shown to be superior to the methyl phos¬ phonate analog which in turn was shown to be more effec¬ tive than the unmodified phosphodiester oligonucleotide. Inhibition of HIV virus replication by a thiophosphorate analog has also been demonstrated. See Matsukara et al, Proc. Natl. Acad. Sci.. USA, 84, 1 (1987).
Phosphorothioate analogs of oligonucleotide probes are also useful as replacements for conventional probes for diagnostic and therapeutic applications. However, only a few techniques have been reported for the synthesis of phosphorothioate analogs of nucleic acids, all of them cumbersome and not well adapted for use with currently available automated nucleic acid synthesizers. One reported synthetic technique, for example, uses presynthesized nucleotide di ers. The synthesis of
the full array of sixteen dimers necessary for the proce¬ dure is both laborious and expensive. (Connoly et al., Biocheπt.. 23, 3443 (1984).
A more preferred procedure would permit use of the highly reactive, commercially available nucleoside- phosphoramidite monomers currently employed with nucleic acid synthesizers. Such monomers are actually used in processes for preparing phosphorothioate analogs. How¬ ever, the sulfurization of phosphorous in the phosphite intermediate has been very troublesome. For example, elemental sulfur in pyridine at room temperature requires up to 16 hours to produce the internucleotide phosphorothioate triester 12 as shown in Fig. I. (P.S. Nelson, et al., J. Orσ. Chem.. 49, 2316 (1984); P.M.S. Burgers, et al., Tet. Lett.. 40, 3835 (1978)). A similar procedure using elemental sulfur, pyridine and carbon disulfide permitted sulfurization to be done at room temperature within 2 hours. B.A. Connolly, et al., Biochem.. 23, 3443 (1984). The triester is convertible to the phosphorothioate . by base catalyzed removal of substituent "R."
Carrying out the sulfurization at 60*C in 2,6- lutidine requires 15 minutes during automated, solid phase synthesis of phosphothioates from Compound 11. .J. Stec et al., J. Am. Chem. Soc.. 106, 6077 (1984). However, most automated synthesizers do not have provisions for heating the column required for performing sulfurization at elevated temperature and vaporization of the solvent at 60*C would be expected to form bubbles in delivery lines which would reduce flow rates and even cause synthesis failures. Furthermore, even a fifteen minute reaction time for sulfurization after the addition of each nucleo- tide makes the procedure far from optimal.
Accordingly, there has gone unmet a need for a process for the preparation of phosphothioate oligonucleo¬ tide analogs that is rapid and that lends itself to use on conventional DNA synthesizers.
Terminology
The following terms are used in this disclosure and claims:
Nucleotide: A subunit of a nucleotide acid consisting of a phosphate group, a 5 carbon sugar ring and nitrogen containing purine or pyrimidine ring. In RNA the
5 carbon sugar is ribose. In DNA, it is 2-deoxyribose.
The term also includes analogs of such subunits.
Nucleotide multimer; A chain of two or more nucleotides linked by phosphorodiester or phosphonodiester bonds, or analogs thereof.
Oligonucleotide; A nucleotide multimer generally about 10 to 125 nucleotides in length, but which may be greater than 125 nucleotides in length. They are usually obtained by synthesis from nucleotide monomers, but may also be obtained by enzymatic means.
Nucleotide multimer probe: A nucleotide multimer having a nucleotide sequence complementary with a target nucleotide sequence contained within a second nucleotide multimer, usually a polynucleotide. Usually the probe is selected to be perfectly complementary to the corresponding base in the target sequence. However, in some cases it may be adequate or even desirable that one or more nucleotides in the probe not be complementary to the corresponding base in the target sequence, or that various moieties of synthetic origin either replace a nucleotide within the probe or be inserted between bases of the probe. Typically, the probe is labeled when used for diagnostic purposes.
Oligonucleotide probe: A probe of synthetic or enzymatic origin usually having less than about 125 nucleotides, but which may contain in excess of 200 nucleotides. Hybridization: The formation of a "hybrid", which is the complex formed between two nucleotide multi- mers by Watson-Crick base pairings between the complemen¬ tary bases.
Summary of the Invention The present invention then provides a reagent which is suitable for the convenient and efficient sul¬ furization of organic phosphites (i.e. trivalent phosphor¬ us bonded to three oxy groups with at least one thereof being an organic-oxy group) and organic phosphonous esters (i.e. trivalent phosphorous bonded to only two oxy groups) , to form the corresponding thiophosphorus acid derivatives (specifically, phosphorothioates or phosphononothioates, respectively) . The invention is particularly suited to sulfurizing a suitably protected inter-nucleotide, either 3'-5' or 2'-5* phosphite or phosphonous linkages contained in oligonucleotides and ribonucleotide multimers in solution or on a solid support for the manual or automated synthesis of phosphothioate oligonucleotides. Accordingly, the present invention provides, in one aspect, a reagent and process using that reagent suitable for adding "sulfur" to a phosphite or phosphonous intermediate such as the kind H (see Fig. 1 in which some preferred substituents are listed) to produce a phosorothioate or phosphonothioate of the kind 12. (see Fig. 1) . It should be noted that for compounds H the inter-nucleotide phosphite or phosphonous bond (and the inter-nucleotide phosphorothioate or phosphonothioate bond
of 12.) is shown between the 3 '-hydroxyl of one nucleoside and the 5'-hydroxyl group of another nucleoside. However, those bonds can be between any two hydroxyl groups of two nucleosides, for example, between the 2' and 5* hydroxyls, or between the hydroxyl group of a nucleoside and that of a non-nucleoside moiety or even between two non-nucleoside moieties. The reagent comprises a mixture of elemental sulfur, a solvent for sulfur, and a tertiary alkyl amine. The preferred reagent is: 0.2M elemental sulfur in a mixture comprising 50% carbon disulfide and 50% diisopropylethylamine. Other reagents of the present invention include:
(i) 0.2M elemental sulfur in a mixture comprising 50% carbon disulfide and 50% triethyla ine; (ii) 0.2M elemental sulfur in a mixture comprising carbon disulfide (25%) , pyridine (25%) and triethylamine (50%) . The above reagents can rapidly sulfurize the phosphite or phosphonous intermediates of the kind IS at room temperature in just about 45 seconds, eliminating the need to choose between extended reaction times required for the sulfurization step if it is to be done at room temperature, or the use of elevated temperatures to achieve more rapid sulfurization as required by prior art processes. Fig. 3 illustrates a sulfurization process according to the invention as embodied in the synthesis of phosphorothioate analogs of oligonucleotides.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 shows the sulfurization of an oligonu¬ cleotide phosphite or phosphonous ester to form a
phosphorothioate triester, or phosphonothioate diester, of a nucleic acid, some preferred substituents listed.
Fig. 2 illustrates the formation of an oligonu¬ cleotide phosphite triester or phosphonous diester useful in the invention, with some preferred substituents listed.
Fig. 3 illustrates assembly of an oligonucleo¬ tide phosphorothioate, involving sulfurization of oligonu¬ cleotide phosphites using a reagent of the present inven¬ tion and its conversion to the corresponding phosphorothi- oate.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
As described above, the reagent of the present invention comprises a mixture of elemental sulfur, an organic solvent for sulfur, and a non-aromatic tertiary amine. By a "non-aromatic" amine is meant an amine which is not a member of an aromatic ring. However this term does not exclude an aromatic group bonded to the nitrogen of an amine group. The solvent for sulfur can be selected from solvents such as carbon disulfide, toluene, benzene or ethyl alcohol. Carbon disulfide is preferred as it is a particularly effective solvent for sulfur. The mixture can optionally include other substances, for example aromatic amines, such as pyridine. The useful tertiary amines include, for example, triethylamine and diisopro- pylethylamine. Diisopropylethylamine is preferred.
The composition of the reagent can vary over a wide range and the particular formulation which yields the best results can depend upon the phosphite or phosphonous ester being sulfurized. However, the most effective formulation of the reagent for a specific reaction can be determined by varying the components of the mixture. In addition, particular formulations may be found practically difficult to work with. For example, it was found that in
a formulation in which l,8-diazabicyclo[5,4,0]undec-7-ene was used as the tertiary amine, sulfur precipitated out from the carbon disulfide solution.
The reagents of the present invention, then, are useful for the sulfurization of organic phosphites or phosphonous esters to form the corresponding phosphorothioate. The starting organophosphorus compound, and its corresponding phosphorothioate produced by the method of the present invention, have the formulae:
In the above formulae, R1f R2, and R3 may be the same or different and are preferrably selected from organic moieties such as optionally substituted alkyl, alkoxy, phenyl, phenoxy, and tertiary a ino, and analogues of the foregoing. In particular, R, and Rj may be ribonucleosides and deoxyribonucleosides.
The reagents of the present invention are particularly useful in the synthesis of phosphorothioate analogs of oligonucleotides from a phosphite or phospho¬ nous ester in which R1 and R? are nucleosides, particularly suitably protected nucleosides. In the case where it is desired to synthesize simply a phosphorothioate analog of a nucleotide multimer, then R3 is a group which can be selectively removed (cleaved) following sulfurization. Examples of such groups include methoxy, and β-cyanoethoxy. However, if it is desired to produce a phosphonothioate analog of a nucleotide multimer (i.e., an analog in which a phosphonous linking group has an 0» replaced with S=) ,
then R3 need not be a group which can be selectively removed following sulfurization. For example, R3 could be methyl. Phosphites and phosphonous esters of the foregoing type are readily obtained using the processes of U.S. Patent No. 4.625,677 and U.S. Patent No. 4,458,066 (the disclosures of these patents, and all other references cited herein, being incorporated into this application by reference) .
Figure 2 illustrates the assembly of a dinucleo- side phosphite or phosphonous ester 15. from compounds of the type 13. (phosphoramidites or phosphona idites) and 14 (nucleotides) . However, it will be appreciated that higher oligomers can be obtained by sequential additions of phosphoramidites according to known procedures. Sulfurization is preferably carried out after the addition of each nucleoside although sulfurization may be deferred and carried out on the assembled oligomer. A preferred reagent for the sulfurization of phosphites or phosphonous esters, particularly the internucleotides obtained from the phosphoramidite process, is 0.2M elemental sulfur dissolved in an equal volume mixture of carbon disulfide and diisopropylethylamine.
Examples 1 and 2 below describe in detail the use of a sulfurizing reagent of the present invention for automated synthesis of phosphorothioates of a different nucleotide multimers. Examples 3 and 4 describe the use of a different sulfurizing reagent of the present invention for automated synthesis of nucleotide multimers. Examples 5 and 6 are similar to Examples 1 through 4 but illustrate the use of different reagents. Example 7 describes the use of a further sulfurizing agent of the present invention for automated synthesis of various phosphorothioate nucleotide multimers, while Example 8 is similar to Example 7 but describes the use of different
reagents. Examples 9 through 11 also describe the use of sulfurizing reagents of the present invention in the automated synthesis of various nucleotide multimers. Example 12 illustrates the Tm (melting temperature) of hybrids formed by the hybridization of phosphorothioate analogs with a complementary RNA sequence. Example 1
Automated Synthesis of Phosphorothioate Analog of TTTT Figure 3 illustrates the scheme for the syn¬ thesis of the phosphorothioate analog of TTTT
Materials: Gold label elemental sulfur, carbon disulfide and diisopropylethylamine ("DIEA") were purchased from Aldrich Fine Chemicals, Milwaukee, Wiscon- sin. Nucleoside phosphoramidites, 15-umol T-column, Tetrazole and Cap B (10% dimethylamino pyridine (DMAP) in tetrahydrofuran (THF) were purchased from Biosearch, Inc., San Rafael, California. Cap A (10% acetic anhydride (AC20) in THF) was prepared from distilled acetic anhydride (Aldrich). 2.5% trichloroacetic acid in dichloromethane was prepared from gold label trichloroacetic acid (Aldrich) . Acetonitrile, dichloromethane and tetrahydro¬ furan, all containing less than 0.002% water were pur¬ chased from J.T. Baker. The scheme of Figure 3 outlines the steps involved in the automated synthesis of a nucleotide tetra er involving automated sulfurization of the phos¬ phite intermediate 2. Synthesis was performed on Bio¬ search 8750 DNA synthesizer using a modified version of the standard synthesis cycle. This modification makes use of an aqueous wash (10% water in 2% pyridine-THF) step prior to the oxidation step. This modification was included to minimize side reactions in the overall syn¬ thesis. Sulfurization was achieved by delivering a 0.2
molar solution of elemental sulfur in 50% carbon disulfide/ 50% diisopropylethylamine, (all percentages by volume unless otherwise indicated) for 15 seconds and letting it stand in the 15 μmol T-column for 30 seconds. After the sulfurization, the column and the delivery lines were washed with acetonitrile before beginning the next cycle of addition of the next base of the sequence.
As shown in Figure 3, the synthetic procedure is initiated using 5'-O-dimethoxytrityl-thymidine linked to controlled pore glass (CPG) , reagent 16, as described, for example, in U.S. Patent No. 4,458,066. The 5'-dimethoxy- trityl (DMT) protecting group is removed using acid catalysis to form the deprotected intermediate 12 which is coupled to the thymidine phosphoramidite 18 to form dimer 1£. Any unreacted 12 is capped by treatment with acetic anhydride and dimethylaminopyridine. The dimer 12 is sulfurized with the same sulfurization reagent consisting of 0.2M sulfur in 50% CS2/50% DIEA to form the phosphorothioate triester 22.' The 5'-protecting group is then removed as before to form dimer 21 and the trimer (not shown) assembled using the thymidine phosphoramidite 18 which is then sulfurized and deprotected, followed by assembly of a tetramer using thymidine phosphoramidite 18. Sulfurization of the tetramer and removal of the 5'- protecting group in the same manner as described, provides tetramer 22.
After tetramer 22. bad been assembled, the resin from the column was transferred into a screw-cap tube and heated with concentrated ammonium hydroxide at 55" for 8- 10 hours to form 22.' Ammonium hydroxide was then evapor¬ ated off to give 300 OD units of the product. An analyti¬ cal examination of the purity was performed by gel elec- trophoresis of 2 OD units of the crude product on a 10%
acrylamide gel containing 7M urea. The product was largely one band (ca, 95%) as shown by UV shadowing.
The extent to which the "sulfur" had been added to the "phosphorus" of the phosphite intermediate was determined by 31P nuclear magnetic resonance (NMR) in D20. Absence of 31P resonance at -2.688 PPM in the NMR spectrum of the phosphorothioate analog of T-T-T-T (31P, 53.866 PPM) indicates that the extent of sulfurization is almost quantitative. Example 2
The use of the sulfurization reagent was then extended to the synthesis of a phosphorothioate analog of a longer nucleotide multimer. This longer multimer was synthesized and deblocked the same way as described in Example 1 but purified by gel electrophoresis (20% acryla¬ mide - 7M urea) . The product was visualized though UV shadowing, the slow moving band was sliced off and ex¬ tracted with 0.1M ammonium acetate (pH 7.2) and desalted on sep-pak followed by a second desalting on Pharmacia's Nap-25 column. Such a desalted multimer was labeled with δ-ATP32 and gel electrophoresed to check the analytical purity. The following phosphorothioate multimer was synthesized (the designation "PS" before the 5' end of the multimer sequence indicating the phophorous of all nucleoside linking groups has been sulfurized) :
A PS-GCTCGTTGCGGGACTTAACCCAACAT ("26-mer") The phosphorothioate analog of the multimer moved very closely in gel electrophoresis to the corresponding normal multimer. Example 3
The procedure of Example 1 was repeated except using as a sulfurization reagent, 0.2M sulfur in 50% CS2/50% triethylamine ("TEA"), to successfully produce PS-TTTT.
Exa ple 4
The procedure of Example 2 was repeated except using as a sulfurization reagent 0.2M sulfur in 50% CS2/50% TEA. In both this Example and in Example 3, the respective sulfurized nucleotide multimers were obtained. However, the sulfurization reagent of Examples 1 and 2 is preferred over that of this Example and Example 3, since it was found that when TEA was used as the tertiary amine rather than DIEA, a brown glue like substance started appearing in the flask after about 6 hours, which was not the case when DIEA was used (the S/CS2/DIEA showing no signs of instability even after 3 days) . Example 5
The procedure of Examples 1 and 2 were repeated to again successfully produce PS-TTTT, and a. (the 26-mer) , but using the methoxy, rather than the β-cyanoethoxy, phosphoramidites of the nucleosides of the formula:
Example 6
The procedures of Examples 3 and 4 were repeated to again successfully produce the PS-TTTT and a. (the 26 er) , but using the methoxy phosphoramidites of Example 5. Example 7
A sulfurization reagent was prepared consisting of 0.2M S in 25% CS2/25% pyridine/50% TEA. The procedure of Example 1 was then repeated except using the foregoing sulfurization reagent. The procedure of Example 2 was
also repeated, to prepare a (the 26-mer) , using the foregoing sulfurization reagent. In addition, using the foregoing sulfurization reagent and the procedure of
Example 2, the following nucleotide multimers were also successfully prepared.
b PS-TTAACCCAACAT (12-mer) c PS-GACTTAACCCAACTAT (15-mer) d PS-GCTCGTTGCGGGACTTAACCC (21-mer) Example 8
The procedure of Example 7 was repeated, but using the methoxy phosphoramidites of the nucleotides, to successfully prepare the sulfurized oligomers a., _, c., and d. Example 9
The procedure of Example 1 was again essentially repeated except using the methyl, rather than the β- cyanoethoxy, phosphonamidite of the T-nucleoside having the formula:
In addition, the sulfurization reagent used was 0.2M sulfur in 25% CS2/25% pyridine/50% TEA. Further, in order to cleave the PS-nucleotide from the resin, the resin was treated at room temperature with 1 ml of a 1:1 (by volume) mixture of ethylenediamine/EtOH for 6 hours.
The resulting product was PS-TTTT in which the nucleosides are linked by methyl phosphonodiester groups. Example 10
The procedure of Example 2 was essentially repeated to prepare the sulfurized 15-mer of c, except using the methyl phosphonamidite and the cleavage procedure Example 9. The resulting oligomer has the sequence c in which the nucleosides are linked by methyl phosphonothioate diester groups. Example 11
Example 9 was repeated except the sulfurizing reagent used as 0.2M sulfur in 50% CS2/50% DIEA (which as previously mentioned is preferred over that using TEA, or that in which pyridine is additionally present) . The resulting product was again the PS-TTTT oligomer in which the nucleotides are linked by methyl phosphonothioate diester groups of the formula: I
CH3-P«S
Example 12
The table below compares the Tm of two phosphor¬ othioate analogs with normal nucleotide multimers. The P32 labeled nucleotide multimer was hybridized with E. coli RNA in 0.48 H phosphate buffer, the hybrid bound to hydroxyapatite resin and the thermal stability measured in 0.1J4 phosphate buffer.
Tm βc Normal Phosphoro ¬ thioate Multimer Mu timer
15-mer 41.8 40.3
26-mer 66. 1 50.9
The foregoing Examples illustrate specific applications of the invention. Other useful applications of the invention which may be a departure from the specific Examples will be apparent to those skilled in the art. Accordingly, the present invention is not limited to those examples described above.
Claims
1. A composition suitable for sulfurization of an organophosphite, comprising a solution of sulfur and a non-aromatic tertiary amine, in a solvent.
2. A composition as defined in claim 1 wherein the tertiary amine is a trialkyl amine.
3. A composition as defined in claim 2 wherein the solvent is an organic solvent.
4. A composition as defined in claim 1 or 2 wherein the solvent is carbon disulfide.
5. A composition as defined in claim 1 wherein the solvent is an organic solvent and the tertiary amine is selected from triethylamine and diisopropylethylamine.
6. A composition as defined in claim 1, 2 or 5 wherein the sulfur concentration is at least about 0.2 M.
7. A composition suitable for sulfurization of an organo-phosphite, comprising a solution of sulfur and a trialkyl amine in an organic solvent with substantially equal parts by weight of the trialkyl amine and the organic solvent.
8. A composition as defined in claim 7 wherein the organic solvent is carbon disulfide and the trialkyl amine is selected from triethylamine and diisopropylethylamine.
9. A method of sulfurizing an organic phospohorus compound selected from an organic phosphite and an organic phosphonous ester to obtain the corresponding organic thiophosphorus acid derivative, comprising contacting the organic phosphorus compound with a solution of sulfur and a non-aromatic tertiary amine, in a solvent.
10. A method as defined in claim 9 wherein the tertiary amine is a trialkyl amine.
11. A method as defined in claim 9 or 10 wherein the solvent is an organic solvent.
12. A method as defined in claim 9 or 10 wherein the solvent is carbon disulfide.
13. A method of sulfurizing an organic phospohorus compound selected from an organic phosphite triester and an organic organophosphonous diester to obtain the cor¬ responding organic thiophosphorus acid derivative, com¬ prising contacting the organic phosphorus compound with a solution of sulfur and a non-aromatic tertiary amine, in a solvent.
14. A method as defined in claim 13 wherein the organic phosphorous compound is selected from a dinucleo- side phosphite triester and a dinucleoside organophospho- nous diester.
15. A method as defined in claim 13 or 14 wherein the tertiary amine is a trialkyl amine.
16. A method as defined in claim 13 or 14 wherein the solvent is an organic solvent.
17. A method as defined in claim 13 or 14 wherein the solvent comprises carbon disulfide.
18. A method as defined in claim 13 or 14 wherein the solvent is an organic solvent and the tertiary amine is a trialkyl amine.
19. A method as defined in claim 14 wherein the solvent comprises carbon disulfide, the tertiary amine is a trialkyl amine.
20. A method as defined in claim 14 wherein the solution of sulfur and a trialkyl amine in the organic solvent has substantially equal parts by weight of the trialkyl amine and the organic solvent, and has a sulfur concentration of at least about 0.2 M.
21. A method as defined in claim 20 wherein the organic solvent is carbon disulfide and the trialkyl amine is selected from triethylamine and diisopropylethylamine.
22. A method of sulfurizing an organic phosphorus compound selected from compounds of the formula:
0R1
R3-P
0R2 wherein R1 and Rj are nucleosides and R3 is optionally a group which can be selectively cleaved following sulfurization, comprising contacting the organic phosphorus compound with a composition comprising a solution of sulfur and a non-aromatic tertiary amine, in an organic solvent, to form a corresponding organic phosphorus thioester of the formula: OR,
R3-P=S 0R2
23. A method as defined in claim 22 wherein the tertiary amine is a trialkyl amine.
24. A method as defined in claim 23 wherein the solvent comprises carbon disulfide.
25. A method as defined in claim 24 wherein the tertiary amine is selected from triethylamine and diiso¬ propylethylamine.
26. A method as defined in claim 25 wherein the sulfur concentration is at least about 0.2 M.
27. A method as defined in claim 26 wherein the solution of sulfur and the trialkyl amine comprises substantially equal parts by weight of the trialkyl amine and the organic solvent.
28. A method as defined in claim 22, 23, or 27, wherein R3 is selected from an optionally substituted alkyl, alkoxy, phenoxy, and tertiary amino, or analogues thereof.
29. A method as defined in claim 22, 23, or 27 wherein Rj is selected from methyl, methoxy, and β- cyanoethoxy.
30. A method as defined in claim 22, 23, or 27 additionally comprising cleaving the leaving group follow¬ ing sulfurization.
31. A method of producing a nucleotide multimer with at least two nucleosides linked by a sulfurized phosphoro¬ thioate or phosphonothioate bond, comprising linking a nucleoside phosphite or nucleoside phosphonite with a second nucleotide then contacting the resulting linked nucleosides with a mixture as defined in claim 1, 2, or 3 so as to sulfurize the internucleotide phosphite or phosphonous group to produce the corresponding inter- nucleotide phosphorothioate or phosphonothioate group.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1990/004994 WO1992004358A1 (en) | 1990-09-04 | 1990-09-04 | Method and reagent for sulfurization of organophosphorous compounds |
AU65239/90A AU642673B2 (en) | 1990-09-04 | 1990-09-04 | Method and reagent for sulfurization of organophosphorous compounds |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1990/004994 WO1992004358A1 (en) | 1990-09-04 | 1990-09-04 | Method and reagent for sulfurization of organophosphorous compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992004358A1 true WO1992004358A1 (en) | 1992-03-19 |
Family
ID=22221025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/004994 WO1992004358A1 (en) | 1990-09-04 | 1990-09-04 | Method and reagent for sulfurization of organophosphorous compounds |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU642673B2 (en) |
WO (1) | WO1992004358A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994015946A1 (en) * | 1993-01-08 | 1994-07-21 | Hybridon, Inc. | Synthesis of dimmer blocks and their use in assembling oligonucleotides |
WO1994017093A1 (en) * | 1993-01-25 | 1994-08-04 | Hybridon, Inc. | Oligonucleotide alkylphosphonates and alkylphosphonothioates |
EP0983233A1 (en) * | 1997-03-03 | 2000-03-08 | Isis Pharmaceuticals, Inc. | Reagent useful for synthesizing sulfurized oligonucleotide analogs |
US6087491A (en) * | 1993-01-08 | 2000-07-11 | Hybridon, Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
US6100027A (en) * | 1995-06-07 | 2000-08-08 | Gen-Probe Incorporated | Nucleic acid probes and amplification oligonucleotides for Neisseria species |
CN102344477A (en) * | 2010-07-27 | 2012-02-08 | 苏州瑞博生物技术有限公司 | Nucleotide and / or oligonucleotide and preparation method thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2536647A (en) * | 1948-03-06 | 1951-01-02 | Monsanto Chemicals | Process of preparing bis (beta-chlorethyl)-para-nitrophenyl thiophosphate |
US2907787A (en) * | 1957-11-13 | 1959-10-06 | Friedrich W Hoffmann | Preparation of phosphono-thiono esters of 2-hydroxyethyl sulfides |
DE1126382B (en) * | 1960-08-17 | 1962-03-29 | Bayer Ag | Process for the preparation of thiophosphoric acid esters |
CA661668A (en) * | 1963-04-23 | H. Ford-Moore Arthur | Manufacture of organic phosphorus compounds | |
US3162570A (en) * | 1962-05-21 | 1964-12-22 | Socony Mobil Oil Co Inc | Organophosphorus compounds as insecticides and nematocides |
US3294874A (en) * | 1962-01-24 | 1966-12-27 | Bayer Ag | Omicron-alkyl-omicron-cycloalkyl-s-alkylthiolphosphoric acid esters |
US3296221A (en) * | 1963-05-13 | 1967-01-03 | Phillips Petroleum Co | Mercapto-substituted thio-phosphites and phosphates and polysulfide polymers thereof |
GB1346409A (en) * | 1962-06-21 | 1974-02-13 | Secr Defence | Manufacture of organic phosphorous compounds containing sulphur |
US4189453A (en) * | 1977-03-10 | 1980-02-19 | Ciba-Geigy Corporation | Processes for the production of sulphur-containing esters of phosphoric acid and phosphorous acid |
-
1990
- 1990-09-04 WO PCT/US1990/004994 patent/WO1992004358A1/en unknown
- 1990-09-04 AU AU65239/90A patent/AU642673B2/en not_active Ceased
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA661668A (en) * | 1963-04-23 | H. Ford-Moore Arthur | Manufacture of organic phosphorus compounds | |
US2536647A (en) * | 1948-03-06 | 1951-01-02 | Monsanto Chemicals | Process of preparing bis (beta-chlorethyl)-para-nitrophenyl thiophosphate |
US2907787A (en) * | 1957-11-13 | 1959-10-06 | Friedrich W Hoffmann | Preparation of phosphono-thiono esters of 2-hydroxyethyl sulfides |
DE1126382B (en) * | 1960-08-17 | 1962-03-29 | Bayer Ag | Process for the preparation of thiophosphoric acid esters |
US3294874A (en) * | 1962-01-24 | 1966-12-27 | Bayer Ag | Omicron-alkyl-omicron-cycloalkyl-s-alkylthiolphosphoric acid esters |
US3162570A (en) * | 1962-05-21 | 1964-12-22 | Socony Mobil Oil Co Inc | Organophosphorus compounds as insecticides and nematocides |
GB1346409A (en) * | 1962-06-21 | 1974-02-13 | Secr Defence | Manufacture of organic phosphorous compounds containing sulphur |
US3296221A (en) * | 1963-05-13 | 1967-01-03 | Phillips Petroleum Co | Mercapto-substituted thio-phosphites and phosphates and polysulfide polymers thereof |
US4189453A (en) * | 1977-03-10 | 1980-02-19 | Ciba-Geigy Corporation | Processes for the production of sulphur-containing esters of phosphoric acid and phosphorous acid |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994015946A1 (en) * | 1993-01-08 | 1994-07-21 | Hybridon, Inc. | Synthesis of dimmer blocks and their use in assembling oligonucleotides |
AU673051B2 (en) * | 1993-01-08 | 1996-10-24 | Hybridon, Inc. | Synthesis of dimer blocks and their use in assembling oligonucleotides |
US6087491A (en) * | 1993-01-08 | 2000-07-11 | Hybridon, Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
US6310198B1 (en) | 1993-01-08 | 2001-10-30 | Avecia Biotechnology Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
WO1994017093A1 (en) * | 1993-01-25 | 1994-08-04 | Hybridon, Inc. | Oligonucleotide alkylphosphonates and alkylphosphonothioates |
US6100027A (en) * | 1995-06-07 | 2000-08-08 | Gen-Probe Incorporated | Nucleic acid probes and amplification oligonucleotides for Neisseria species |
US6541201B1 (en) | 1995-06-07 | 2003-04-01 | Gen-Probe Incorporated | Hybridization assay probes and methods for detecting the presence of neisseria meningitiidis subtypes A, C and L in a sample |
EP0983233A1 (en) * | 1997-03-03 | 2000-03-08 | Isis Pharmaceuticals, Inc. | Reagent useful for synthesizing sulfurized oligonucleotide analogs |
EP0983233A4 (en) * | 1997-03-03 | 2002-03-20 | Isis Pharmaceuticals Inc | REAGENT USED FOR THE SYNTHESIS OF ANALOGS OF SULFURIZED OLIGONUCLEOTIDES |
CN102344477A (en) * | 2010-07-27 | 2012-02-08 | 苏州瑞博生物技术有限公司 | Nucleotide and / or oligonucleotide and preparation method thereof |
CN102344477B (en) * | 2010-07-27 | 2015-04-08 | 苏州瑞博生物技术有限公司 | Nucleotide and / or oligonucleotide and preparation method thereof |
US9567364B2 (en) | 2010-07-27 | 2017-02-14 | Suzhou Ribo Life Sciene Co., Ltd. | Nucleotide and/or oligonucleotide and preparation process thereof |
Also Published As
Publication number | Publication date |
---|---|
AU642673B2 (en) | 1993-10-28 |
AU6523990A (en) | 1992-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5252723A (en) | Method and reagent for sulfurization of organophosphorous compounds | |
US5512668A (en) | Solid phase oligonucleotide synthesis using phospholane intermediates | |
AU739468B2 (en) | Activators for oligonucleotide synthesis | |
Dellinger et al. | Solid-phase chemical synthesis of phosphonoacetate and thiophosphonoacetate oligodeoxynucleotides | |
WO1995032980A1 (en) | Synthesis of oligonucleotides | |
WO1999040101A1 (en) | Synthetic process for the preparation of oligonucleotides, nucleoside synthons used therein, and oligonucleotides prepared thereby | |
JPH08508513A (en) | Method for making a phosphorus-containing covalent bond and its intermediates | |
Froehler | Oligodeoxynucleotide synthesis: H-phosphonate approach | |
EP1246833A1 (en) | Improved synthesis of sulfurized oligonucleotides | |
EP1272501B1 (en) | Process for the preparation of phosphorothioate triesters | |
EP1244682A1 (en) | Process for the preparation of oligomeric compounds | |
US5420330A (en) | Lipo-phosphoramidites | |
WO2002079216A1 (en) | Labeled oligonucleotides, methods for making same, and compounds useful therefor | |
AU642673B2 (en) | Method and reagent for sulfurization of organophosphorous compounds | |
WO1998029429A1 (en) | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | |
JPH09503494A (en) | Building blocks with carbamate internucleoside linkages and novel oligonucleotides derived therefrom | |
Fathi et al. | (Aminomethyl) phosphonate derivatives of oligonucleotides | |
WO1997042202A1 (en) | In situ preparation of nucleoside phosphoramidites and oligonucleotide synthesis | |
US5639875A (en) | Methods for H-phosphonate syntheis of oligonucleotides using triphosgene | |
Thorpe | Reviving H-phosphonate Chemistry: Novel Methods for Sustainable Oligonucleotide Synthesis | |
Strömberg et al. | Synthesis of oligodeoxyribo‐and oligoribonucleotides according to the H‐phosphonate method | |
US6103891A (en) | Method for the synthesis of nucleotide or oligonucleotide phosphoramidites | |
Nawrot et al. | A Novel Class of DNA Analogs Bearing 5′-C-Phosphonothymidine Units: Synthesis and Physicochemical and Biochemical Properties | |
Toulmé et al. | Selecting, preparing, and handling antisense oligodeoxyribonucleotides | |
Usman | Nucleoside phosphoramidites in the automated, solid phase synthesis of oligoribonucleotides and their analogues: the chemical synthesis of an E. coli N-formyl-methionine tRNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU |